HANSOH PHARMA(HK:03692)2026-03-30 02:45Investment Rating - The report does not explicitly state the investment rating for Hansoh Pharma Core Insights - Hansoh Pharma achieved revenue of RMB 15.0 billion in FY25, representing a 23% year-over-year increase. Innovative drug revenue reached RMB 10.2 billion (+30% YoY), while generic drug revenue was RMB 2.7 billion (-4% YoY). Collaboration revenue amounted to RMB 2.1 billion (+35% YoY) [1][4][5] - The proportion of innovative drug and collaboration income increased to 82% of total revenue, indicating a strong focus on innovative products [1][4] - The gross margin stood at 90.0%, down 1 percentage point year-over-year, while the operating profit margin increased by 4 percentage points to 36% due to improved selling expense ratios [5] - The net profit attributable to shareholders was RMB 5.56 billion, reflecting a 27% increase year-over-year, aligning with market expectations [1][5] Segment Analysis - Oncology revenue was RMB 10.0 billion (+23% YoY), accounting for 66% of total revenue. Anti-infective revenue was RMB 1.6 billion (+8% YoY), making up 12% of total revenue. Central nervous system revenue was RMB 1.3 billion (-5% YoY), representing 11% of total revenue. Metabolic and other diseases revenue was RMB 2.2 billion (+67% YoY), also accounting for 11% of total revenue [3][8] - Key milestones include the approval of Aumolertinib for first-line treatment in January 2026, expected to be included in the National Reimbursement Drug List in 2027. The company also completed three overseas licensing deals with a total transaction value exceeding USD 4.54 billion [6][8] - In 2025, the company advanced 8 new innovative drug candidates into clinical development and initiated 7 pivotal Phase III registrational clinical trials [6][8]